Madhu Kumar
Stock Analyst at Goldman Sachs
(2.89)
# 1,765
Out of 5,044 analysts
151
Total ratings
56.86%
Success rate
20.34%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $135.73 | +36.30% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $9.36 | -35.90% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.85 | +4.63% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $11.95 | +42.26% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.55 | +158.06% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $185.05 | -16.24% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $61.99 | -14.50% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $6.49 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $40.29 | +81.19% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $30.05 | +369.22% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $13.22 | +157.19% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.00 | +200.00% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $9.44 | +48.31% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.30 | +103.88% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $16.33 | -69.38% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $3.04 | +163.16% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $9.59 | +828.05% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $7.43 | +1,515.07% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $1.22 | +719.67% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.12 | +547.87% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.63 | +974.38% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $70.59 | -19.25% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.61 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.45 | +61,968.97% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.91 | +238.41% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.75 | +13,224.45% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $29.27 | +19.58% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.48 | +12,449.68% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $11.73 | +241.01% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $30.99 | +1,526.33% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $481.59 | -52.24% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $12.50 | +8,900.00% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.38 | +2,798.55% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $33.78 | -36.35% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $62.56 | -62.44% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $135.73
Upside: +36.30%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $9.36
Upside: -35.90%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.85
Upside: +4.63%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $11.95
Upside: +42.26%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.55
Upside: +158.06%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $185.05
Upside: -16.24%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $61.99
Upside: -14.50%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $6.49
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $40.29
Upside: +81.19%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $30.05
Upside: +369.22%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $13.22
Upside: +157.19%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.00
Upside: +200.00%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $9.44
Upside: +48.31%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.30
Upside: +103.88%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $16.33
Upside: -69.38%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $3.04
Upside: +163.16%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $9.59
Upside: +828.05%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $7.43
Upside: +1,515.07%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $1.22
Upside: +719.67%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.12
Upside: +547.87%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.63
Upside: +974.38%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $70.59
Upside: -19.25%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.61
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.45
Upside: +61,968.97%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.91
Upside: +238.41%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.75
Upside: +13,224.45%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $29.27
Upside: +19.58%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.48
Upside: +12,449.68%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $11.73
Upside: +241.01%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $30.99
Upside: +1,526.33%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $481.59
Upside: -52.24%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $12.50
Upside: +8,900.00%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.38
Upside: +2,798.55%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $33.78
Upside: -36.35%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $62.56
Upside: -62.44%